Stock of the Day

Today's Trend

Immunovant, Inc. (NASDAQ: IMVT) shares have weakened as investors assessed disappointing mid-stage data for IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The company’s decision to discontinue the CLE program removes one development opportunity, although management emphasized that other clinical timelines remain on track.

• IMVT-1402 showed positive trends across multiple measures, with greater IgG reductions associated with better clinical outcomes. The drug also produced a favorable safety and tolerability profile consistent with earlier studies. Immunovant Announces Topline Results from Proof-of-Concept Study
• Immunovant said all other clinical development timelines remain on track, helping preserve potential value from its broader autoimmune and inflammatory disease pipeline. Roivant reports top-line data from IMVT-1402 CLE trial
• A market-data update reported zero shares sold short as of September 24, implying a zero-day short-interest ratio. The figure appears unusual relative to reported trading activity and may have limited significance for investors until confirmed.
• The CLE proof-of-concept study failed to achieve statistical significance on its primary endpoint, the change in CLASI-A score at Week 12. Immunovant concluded the results did not meet its internal threshold for continued development and will halt IMVT-1402’s CLE program. IMVT Ends Cutaneous Lupus Erythematosus Program
• The trial miss and program termination reduce the addressable opportunity for IMVT-1402 and undermine confidence in its efficacy, which are the primary reasons for recent pressure on Immunovant (IMVT).